Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Regular lifestyle counseling can have positive long term clinical outcomes in patients with diabetes.
Read More »Reducing CV Events and All-Cause Mortality For Type 2 Patients
Aggressive Glucose Control Not Recommended During Stroke
Hyperglycemia is associated with worse outcomes during a stroke, but aggressive glucose management does not improve stroke outcomes.
Read More »Skipping Breakfast and Its Long-Term Health Impact on CVD
Do you promote eating breakfast with your patients? What are the risks for skipping breakfast?
Read More »Intensive Lipid Lowering Linked To Neuropathy
Patients with type 2 diabetes on intensive lipid lowering therapy may be at an increased risk for developing secondary neuropathies, based on the results of a recent study.
Read More »Evidence for Lack of a Glucose-Control Legacy Effect
Intensive glycemic control shows benefits with time; however, evidence is showing this effect may wear off.
Read More »Decreased Risk of Mortality Through an Increase of Physical Activity Trajectories
An increase in exercise can save your life -- in more than just heart health.
Read More »CV Benefit of GLP-1 Agonists and SGLT2 Inhibitors Misleading for Black Patients? ADA
Claims of improved cardiovascular outcomes from GLP-1 agonists and SGLT2 inhibitors not proven significant for black patients.
Read More »Better Outcomes with Intensive Control of BP, Adiposity and Lipids Than A1c
It has been known for so long that optimal glycemic control in type 1 diabetes can decrease the risk of micro and macrovascular complications, but why is the risk still high despite intensive glycemic control?
Read More »The ASCEND Study – Aspirin for Prevention of Cardiovascular Events
The study findings demonstrate a balance between cardiovascular protection and major bleeding.
Read More »Cardiovascular Benefits of Oral GLP-1RA in High-Risk Patients with Type 2 Diabetes
Results from the recently published PIONEER trial series demonstrate the overall diabetic benefits of oral semaglutide, a novel GLP-1 receptor agonist.
Read More »